Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Read More…
Industry, Sector and Symbol
Industry N/A
Sub-IndustryPharmaceuticals
SectorN/A
WebN/A
PhoneN/A
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees135,100
Next Earnings Date4/21/2020 (Estimated)
OptionableOptionable
Johnson & Johnson (NYSE:JNJ) Frequently Asked Questions
What is Johnson & Johnson's stock symbol?
Johnson & Johnson trades on the New York Stock Exchange (NYSE) under the ticker symbol "JNJ."
How often does Johnson & Johnson pay dividends? What is the dividend yield for Johnson & Johnson?
Johnson & Johnson declared a quarterly dividend on Thursday, January 2nd. Shareholders of record on Tuesday, February 25th will be paid a dividend of $0.95 per share on Tuesday, March 10th. This represents a $3.80 dividend on an annualized basis and a dividend yield of 2.53%. The ex-dividend date is Monday, February 24th. View Johnson & Johnson's Dividend History.
How will Johnson & Johnson's stock buyback program work?
Johnson & Johnson announced that its board has approved a stock buyback program on Monday, December 17th 2018, which allows the company to buyback $5,000,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to reacquire up to 1.5% of its stock through open market purchases. Stock buyback programs are often a sign that the company's leadership believes its stock is undervalued.
How were Johnson & Johnson's earnings last quarter?
Johnson & Johnson (NYSE:JNJ) issued its quarterly earnings results on Wednesday, January, 22nd. The company reported $1.88 EPS for the quarter, topping the Zacks' consensus estimate of $1.87 by $0.01. The firm earned $20.75 billion during the quarter, compared to analysts' expectations of $20.83 billion. The business's quarterly revenue was up 1.7% on a year-over-year basis. During the same period last year, the business earned $1.97 earnings per share. View Johnson & Johnson's Earnings History.
When is Johnson & Johnson's next earnings date?
What guidance has Johnson & Johnson issued on next quarter's earnings?
Johnson & Johnson issued an update on its FY20 earnings guidance on Wednesday, January, 22nd. The company provided earnings per share guidance of $8.95-9.10 for the period, compared to the Thomson Reuters consensus EPS estimate of $9.09. The company issued revenue guidance of +4.5-5.5% yr/yr to $85.8-86.2 billion, compared to the consensus revenue estimate of $85.52 billion.
What price target have analysts set for JNJ?
13 Wall Street analysts have issued 1 year price objectives for Johnson & Johnson's shares. Their forecasts range from $147.00 to $173.00. On average, they anticipate Johnson & Johnson's share price to reach $162.27 in the next twelve months. This suggests a possible upside of 8.1% from the stock's current price. View Analyst Price Targets for Johnson & Johnson.
What is the consensus analysts' recommendation for Johnson & Johnson?
13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Johnson & Johnson in the last year. There are currently 3 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Johnson & Johnson.
Has Johnson & Johnson been receiving favorable news coverage?
News articles about JNJ stock have been trending somewhat positive recently, according to InfoTrie. InfoTrie rates the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Johnson & Johnson earned a coverage optimism score of 2.0 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Johnson & Johnson.
Who are some of Johnson & Johnson's key competitors?
Some companies that are related to Johnson & Johnson include AbbVie (ABBV), The Medicines (MDCO), Assembly Biosciences (ASMB), Ampio Pharmaceuticals (AMPE), Melinta Therapeutics (MLNT), Acura Pharmaceuticals (ACUR), Akorn (AKRX), Allergan (AGN), BioDelivery Sciences International (BDSI), Bristol-Myers Squibb (BMY), Corcept Therapeutics (CORT), Cumberland Pharmaceuticals (CPIX), Eli Lilly And Co (LLY), Endo International (ENDP) and Horizon Therapeutics (HZNP).
What other stocks do shareholders of Johnson & Johnson own?
Who are Johnson & Johnson's key executives?
Johnson & Johnson's management team includes the folowing people:
- Mr. Alex Gorsky, Chairman & CEO (Age 59)
- Mr. Joseph J. Wolk CPA, Exec. VP & CFO (Age 52)
- Dr. Paulus A. Stoffels, Chief Scientific Officer (Age 57)
- Mr. Michael H. Ullmann, Exec. VP & Gen. Counsel (Age 60)
- Mr. Joaquin Duato, Vice Chairman of Exec. Committee (Age 56)
Who are Johnson & Johnson's major shareholders?
Johnson & Johnson's stock is owned by many different of retail and institutional investors. Top institutional investors include State Street Corp (5.76%), Bank of New York Mellon Corp (1.25%), Massachusetts Financial Services Co. MA (1.04%), FMR LLC (0.68%), Franklin Resources Inc. (0.48%) and Charles Schwab Investment Management Inc. (0.47%). Company insiders that own Johnson & Johnson stock include Alex Gorsky, Charles Prince, Hubert Joly, Joaquin Duato, Kathryn E Wengel, Marillyn A Hewson, Michael E Sneed, Peter Fasolo and Ronald A Kapusta. View Institutional Ownership Trends for Johnson & Johnson.
Which institutional investors are selling Johnson & Johnson stock?
JNJ stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Assenagon Asset Management S.A., Yacktman Asset Management LP, Great West Life Assurance Co. Can, PGGM Investments, DNB Asset Management AS, Public Sector Pension Investment Board and Swiss National Bank. Company insiders that have sold Johnson & Johnson company stock in the last year include Kathryn E Wengel and Michael E Sneed. View Insider Buying and Selling for Johnson & Johnson.
Which institutional investors are buying Johnson & Johnson stock?
JNJ stock was purchased by a variety of institutional investors in the last quarter, including Johanson Financial Advisors Inc., Amundi Pioneer Asset Management Inc., M&G Investment Management Ltd., Franklin Resources Inc., Bank of New York Mellon Corp, Massachusetts Financial Services Co. MA, FMR LLC and Fiera Capital Corp. Company insiders that have bought Johnson & Johnson stock in the last two years include Charles Prince, Hubert Joly and Marillyn A Hewson. View Insider Buying and Selling for Johnson & Johnson.
How do I buy shares of Johnson & Johnson?
Shares of JNJ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Johnson & Johnson's stock price today?
One share of JNJ stock can currently be purchased for approximately $150.13.
MarketBeat Community Rating for Johnson & Johnson (NYSE JNJ)
MarketBeat's community ratings are surveys of what our community members think about Johnson & Johnson and other stocks. Vote "Outperform" if you believe JNJ will outperform the S&P 500 over the long term. Vote "Underperform" if you believe JNJ will underperform the S&P 500 over the long term. You may vote once every thirty days.
